firstly demonstrates the utility of a novel metabolic agent, GLP-1, in attenuating myocardial stunning after ischemiareperfusion in canine models [97]
P.HowesR
G-protein diseases furnish a model for the turn-on switch
doi: 10.1371/journal.pone.0288718 Summary Keywords GLP-1 receptor agonists, gut microbiome modulation, incretinmicrobiota axis, metabolism, therapeutic response variability Citation De La Motte LR, Carreras F and Drago L (2026) The gut microbiota as a potential determinant of response to GLP-1 receptor agonists: a narrative review
This guide reflects Novi's current published program terms, the FDA's April 30, 2026 proposed rule on compounded GLP-1 medications, and the June 29, 2026 public comment deadline
Blended peptide formulations also reduce handling variability and streamline experimental preparation workflows